je.st
news
Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA (pembrolizumab)
2017-01-09 14:00:47| Merck.com - Product News
Dateline City: WILMINGTON, D.E. & KENILWORTH, N.J. Additional pivotal studies evaluating Incytes IDO1 inhibitor in combination with Mercks anti-PD-1 therapy in patients with non-small cell lung, renal, bladder and head and neck cancers expected to start in 2017 WILMINGTON, D.E. & KENILWORTH, N.J. Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical development program investigating the combination of epacadostat, Incytes investigational oral selective IDO1 inhibitor, with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy. Language: English read more
Tags: with
development
program
combination
Category:Biotechnology and Pharmaceuticals